Copyright
©The Author(s) 2022.
World J Gastrointest Surg. Nov 27, 2022; 14(11): 1260-1271
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1260
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1260
Table 9 Changes in platelet counts in group D (22-28 d of treatment)
| Baseline | Day 5 | Day 14 | Day 24 | Post-treatment | Change | |
| n | 9 | 9 | 7 | 8 | 9 | 9 |
| mean ± SD (× 109/L) | 35.56 ± 11.72 | 41.22 ± 17.41 | 50.29 ± 33.76 | 83.88 ± 34.87 | 90.89 ± 71.85 | 55.33 ± 63.15 |
| Median (× 109/L) | 34.00 | 37.00 | 42.00 | 84.50 | 79.00 | 45.00 |
| IQR (× 109/L) | 27.50-38.00 | 33.00-51.50 | 39.00-45.00 | 47.75-118.00 | 36.50-126.50 | 5.50-93.00 |
| Min, max (× 109/L) | 25.00, 64.00 | 16.00, 78.00 | 18.00, 124.00 | 42.00, 127.00 | 29.00, 254.00 | -12.00, 190.00 |
- Citation: Ding JN, Feng TT, Sun W, Cai XY, Zhang Y, Zhao WF. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study. World J Gastrointest Surg 2022; 14(11): 1260-1271
- URL: https://www.wjgnet.com/1948-9366/full/v14/i11/1260.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v14.i11.1260